Arrowhead rises as U.S. FDA grants breakthrough tag for rare blood fat disorder drug

Shares of drug developer Arrowhead Pharmaceuticals ARWR.O rise 1% to $57.23 premarket

Co says U.S. FDA grants breakthrough tag to its experimental drug plozasiran for treating patients with severe hypertriglyceridemia

Hypertriglyceridemia involves very high blood fat levels, raising risk of acute pancreatitis

Co's plozasiran aims to lower blood fats by blocking apoC-III, a protein that slows fat breakdown - ARWR

ARWR plans to finish late-stage trials by mid-2026

Co expects to file for FDA approval by end-2026 and seek global clearances later

Up to last close, stock up ~199%